MY182553A - Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions - Google Patents

Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions

Info

Publication number
MY182553A
MY182553A MYPI2014001376A MYPI2014001376A MY182553A MY 182553 A MY182553 A MY 182553A MY PI2014001376 A MYPI2014001376 A MY PI2014001376A MY PI2014001376 A MYPI2014001376 A MY PI2014001376A MY 182553 A MY182553 A MY 182553A
Authority
MY
Malaysia
Prior art keywords
ylmethyl
tetrahydro
quinoline
conditions
skin diseases
Prior art date
Application number
MYPI2014001376A
Other languages
English (en)
Inventor
Mohammed I Dibas
John E Donello
Daniel W Gil
Edward C Hsia
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47178364&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY182553(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of MY182553A publication Critical patent/MY182553A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
MYPI2014001376A 2011-11-10 2012-11-08 Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions MY182553A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161558104P 2011-11-10 2011-11-10
PCT/US2012/064075 WO2013070861A1 (en) 2011-11-10 2012-11-08 Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions

Publications (1)

Publication Number Publication Date
MY182553A true MY182553A (en) 2021-01-25

Family

ID=47178364

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2014001376A MY182553A (en) 2011-11-10 2012-11-08 Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions

Country Status (22)

Country Link
US (4) US20130123303A1 (https=)
EP (3) EP2776034B1 (https=)
JP (2) JP6359456B2 (https=)
KR (1) KR102004563B1 (https=)
CN (1) CN104136029A (https=)
AR (1) AR088845A1 (https=)
AU (2) AU2012335803B2 (https=)
BR (1) BR112014011336A2 (https=)
CA (1) CA2855005C (https=)
CL (1) CL2014001242A1 (https=)
DK (1) DK2776034T3 (https=)
ES (1) ES2635421T3 (https=)
IL (3) IL232483B (https=)
MX (1) MX350662B (https=)
MY (1) MY182553A (https=)
PH (1) PH12014501051A1 (https=)
RU (2) RU2630978C2 (https=)
SG (3) SG11201402246RA (https=)
TW (3) TWI708604B (https=)
UA (1) UA109359C2 (https=)
WO (1) WO2013070861A1 (https=)
ZA (1) ZA201403396B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9283217B2 (en) 2011-11-10 2016-03-15 Allergan, Inc. Pharmaceutical compositions comprising 7-(1 H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
BR112015027984A2 (pt) * 2013-05-06 2017-09-05 Allergan Inc Agonistas alfa adrenérgicos para o tratamento de lesão de tecido
FR3061434B1 (fr) * 2017-01-04 2019-07-12 Pierre Fabre Dermo-Cosmetique Composition cosmetique comprenant une association d'huile de pongamia et de pentylene glycol 4-t-butylcyclohexanol pour lutter contre la rosacee
RU2727695C1 (ru) * 2020-02-13 2020-07-22 Мурад Умарович Магомедов Способ комплексного лечения ринофимы

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69940227D1 (de) * 1998-05-08 2009-02-12 Univ Miami Verwendung von sub-antimikrobiellen tetracyclinen zur Behandlung von okularer Rosacea
US6242442B1 (en) * 1998-12-17 2001-06-05 Alcon Laboratories, Inc. Brinzolamide and brimonidine for treating ocular conditions
US20010049369A1 (en) * 2000-02-10 2001-12-06 Jablonski Monica M. Brimonidine compositions and methods for retinal degeneration
US6468989B1 (en) 2000-07-13 2002-10-22 Dow Pharmaceutical Sciences Gel compositions containing metronidazole
US6387383B1 (en) 2000-08-03 2002-05-14 Dow Pharmaceutical Sciences Topical low-viscosity gel composition
US20020198209A1 (en) 2001-05-03 2002-12-26 Allergan Sales Inc. Compositions having enhanced pharmacokinetic characteristics
US6680062B2 (en) 2001-10-05 2004-01-20 Color Access, Inc. Anti-irritating rosacea treatment
US7030149B2 (en) * 2002-04-19 2006-04-18 Allergan, Inc. Combination of brimonidine timolol for topical ophthalmic use
US20040146539A1 (en) * 2003-01-24 2004-07-29 Gupta Shyam K. Topical Nutraceutical Compositions with Selective Body Slimming and Tone Firming Antiaging Benefits
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US20050020600A1 (en) * 2003-07-23 2005-01-27 Scherer Warren J. Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists
KR20060109947A (ko) * 2003-11-20 2006-10-23 오쎄라 파마슈티걸즈, 인크. 황반 변성 및 다른 안과 질환의 개선
US7812049B2 (en) 2004-01-22 2010-10-12 Vicept Therapeutics, Inc. Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
JP4955543B2 (ja) * 2004-05-25 2012-06-20 サンズローザ ファーマシューティカル ディヴェロップメント インコーポレイテッド 炎症性皮膚疾患を治療又は予防するための化合物、製剤及び方法
US20070203144A1 (en) * 2006-01-17 2007-08-30 Allergan, Inc. Use of Memantine and Brimonidine to Attenuate Vitreoretinal Vascular Endothelial Growth Factor (VEGF) Protein Levels in Animals
US7323477B2 (en) 2006-02-02 2008-01-29 Allergan, Inc. 7-((1H-imidazol-4-yl)methyl)-5,6,7,8-tetrahydroquinoline
RU2321399C1 (ru) * 2006-06-01 2008-04-10 Федеральное государственное учреждение "Нижегородский научно-исследовательский кожно-венерологический институт Федерального агентства по здравоохранению и социальному развитию" Способ лечения больных розацеа
US20090005450A1 (en) * 2007-04-09 2009-01-01 Belinda Tsao Nivaggioli Use of creatine compounds for the treatment of eye disorders
US20090061020A1 (en) * 2007-08-31 2009-03-05 Theobald Klaus P Brimonidine Compositions for Treating Erythema
WO2009052073A2 (en) * 2007-10-18 2009-04-23 Allergan, Inc. Method of treating sensorimotor disorders with alpha-2 adrenergic receptor agonists
US20100203165A1 (en) * 2008-08-01 2010-08-12 Gerald Horn Compositions and methods for treatment of disorders or conditions of the eye
US20100028266A1 (en) * 2008-08-01 2010-02-04 Alpha Synergy Development. Inc. Composition and methods for treating allergic response
FR2942138A1 (fr) 2009-02-16 2010-08-20 Galderma Res & Dev Association de composes pour le traitement ou la prevention des affections dermatologiques
CA2779063A1 (en) * 2009-10-26 2011-05-05 Galderma Pharma S.A. Methods of treating or preventing acute erythema
US8394800B2 (en) * 2009-11-19 2013-03-12 Galderma Laboratories, L.P. Method for treating psoriasis
US8513247B2 (en) * 2010-03-26 2013-08-20 Galderma Laboratories, L.P. Methods and compositions for safe and effective treatment of erythema
MX2012010823A (es) * 2010-03-26 2012-10-10 Galderma Res & Dev Metodos y composiciones mejoradas para tratamiento seguro y efectivo de telangiectasia.
WO2012017077A1 (en) * 2010-08-06 2012-02-09 Galderma Research & Development Combination of compounds for treating or preventing skin diseases

Also Published As

Publication number Publication date
AU2012335803A1 (en) 2014-05-29
EP3184110A1 (en) 2017-06-28
US9308201B2 (en) 2016-04-12
DK2776034T3 (en) 2017-07-10
US20160051534A1 (en) 2016-02-25
SG11201402246RA (en) 2014-06-27
UA109359C2 (xx) 2015-08-10
CN104136029A (zh) 2014-11-05
JP6359456B2 (ja) 2018-07-18
IL261269A (en) 2018-10-31
SG10201609145PA (en) 2016-12-29
WO2013070861A1 (en) 2013-05-16
JP2017149767A (ja) 2017-08-31
CL2014001242A1 (es) 2014-11-14
ZA201403396B (en) 2015-07-29
CA2855005A1 (en) 2013-05-16
AR088845A1 (es) 2014-07-10
TWI580424B (zh) 2017-05-01
RU2667645C1 (ru) 2018-09-21
SG10201809506TA (en) 2018-11-29
IL232483B (en) 2018-10-31
ES2635421T3 (es) 2017-10-03
RU2630978C2 (ru) 2017-09-15
EP2776034A1 (en) 2014-09-17
MX2014005640A (es) 2014-09-22
TW201328694A (zh) 2013-07-16
AU2016216627B2 (en) 2017-10-19
IL268757A (en) 2019-10-31
AU2012335803B2 (en) 2016-05-26
EP2776034B1 (en) 2017-03-22
US20170095466A1 (en) 2017-04-06
KR102004563B1 (ko) 2019-07-26
EP3763370A1 (en) 2021-01-13
NZ624771A (en) 2016-11-25
BR112014011336A2 (pt) 2017-05-02
JP2014533271A (ja) 2014-12-11
AU2016216627A1 (en) 2016-09-08
RU2014122758A (ru) 2015-12-20
US20130123303A1 (en) 2013-05-16
TWI708604B (zh) 2020-11-01
IL232483A0 (en) 2014-06-30
EP3184110B1 (en) 2020-10-07
TW201713338A (zh) 2017-04-16
US20150231128A1 (en) 2015-08-20
MX350662B (es) 2017-09-13
PH12014501051A1 (en) 2022-11-02
CA2855005C (en) 2016-11-22
KR20140107237A (ko) 2014-09-04
JP6526737B2 (ja) 2019-06-05
TW202014189A (zh) 2020-04-16

Similar Documents

Publication Publication Date Title
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
EA201592250A1 (ru) Пиразолопирролидиновые производные и их применение в лечение заболеваний
MX2013012588A (es) Inhibidores de cinasa.
MY186126A (en) Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor
UA114726C2 (uk) 1,4-дизаміщені аналоги піридазину та способи лікування пов'язаних з дефіцитом smn станів
MX2009010407A (es) Derivados fluorados de deferiprona.
UA116774C2 (uk) Інгібітори серин/треонінкінази
PH12012500622A1 (en) Compounds for the treatment of dyslipidemia and related diseases
MX2010007683A (es) Derivados heterociclicos fusionados y metodos de uso como inhibidores de c-met.
MX2015016425A (es) Derivados de pirazolo-pirrolidin-4-ona y su uso en el tratamiento de enfermedades.
MX2011009709A (es) Compuestos para el tratamiento de la inflamacion y del dolor.
GEP20135806B (en) Lactams as beta secretase inhibitors
MX2010009624A (es) Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1 y cx3cr1.
MX2013002208A (es) Derivados de sulfonilpiperazina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes.
IL268757A (en) Pharmaceutical preparations containing 7-(H1-imidazol-4-ylmethyl)-8,7,6,5-tetrahydroquinoline for the treatment of skin diseases and conditions
IN2013DN02555A (https=)
MX2014014066A (es) Compuestos de cromano.
MX2014014814A (es) Composicion farmaceutica para el tratamiento de inflamacion y dolor.
BR112014016450A2 (pt) composto antagonista de leucotrieno b4
MX348723B (es) Combinaciones de solifenacina y estimulantes salivales para el tratamiento de la vejiga hiperactiva.
PH12012501476A1 (en) Aminoquinoline derivatives
MX2014011843A (es) Compuestos para usarse en el tratamiento de neuroblastoma, sarcoma de ewing o rabdomiosarcoma.
MY166057A (en) Carbocyclic nucleosides and their pharmaceutical use and compositions
MX2014000870A (es) Composiciones farmaceuticas que comprenden 4-bromo-n-(imidazolidin -2-iliden)-1h-benzimidazol-5-amina para tratar enfermedades de la retina.
PH12015502560A1 (en) Use of a thiazolo pyrimidinone for the treatment of inflammatory bowel disease